We are currently nowhere near having conclusive results regarding the safety or efficacy of CAR-T cell therapy in breast cancer; however, recent results from a phase I clinical trial which investigated the safety of CAR-T cells directed against c-met (anti-c-met-CAR-T cells), intratumorally injected into patients with TNBC, demonstrated that c-Met-CAR-T cell therapy was well-tolerated by patients and elicited an inflammatory response within TNBC tumours. This evidence concerns the gene MET and breast cancer.